• 제목/요약/키워드: Head&Neck Cancer

검색결과 1,144건 처리시간 0.023초

원발성(原發性) 후두(候頭) 임파종(淋巴腫) (Localized Primary Laryngeal Lymphoma Treated by Irradiation)

  • 김귀언;서창옥;김주항;김병수;이광길;김광문;홍원표
    • 대한두경부종양학회지
    • /
    • 제1권1호
    • /
    • pp.81-86
    • /
    • 1985
  • A case of primary laryngeal non-Hodgkin's lymphoma is detailed with a review of the literature, on this rare site of presentation. Histologic findings and radio-therapeutic technique are included with longterm follow-up data. Local radiotherapy is a curative treatment of choice due to longterm NED survival with preservation of voice.

  • PDF

국소 진행된 갑상선암의 수술 - 기관 및 후두, 식도 침범의 치료 (Surgical Treatment in Locally Advanced Thyroid Cancer - Trachea, Larynx, Esophagus Invasion Management)

  • 이국행;강주용
    • International journal of thyroidology
    • /
    • 제11권2호
    • /
    • pp.99-108
    • /
    • 2018
  • Most thyroid cancers are well-differentiated cancers and have a very good prognosis. About 10% of thyroid cancer, however, invades the surrounding tissues, causing local recurrence and distant metastasis, and eventually affecting survival rate. In locally advanced thyroid cancers, the invasion of trachea, larynx and esophagus, can be occurred by primary tumor and may also result in lymph nodes metastasis. Surgical resection is still mainstay for the treatment of locally advanced thyroid cancer. The main purpose of the surgical resection is to eliminate the cancer completely, therefore, it can cause many complications such as dysfunction of the larynx, trachea and esophagus. It can have a serious effect on the quality of life, therefore there is still controversy on the extent of the surgery. The authors compare and analyze the opinions which were already discussed in the literatures published so far. These will help to select the surgical method.

예후가 좋지 않은 갑상선암에 대한 최신 치료 방침 (Recent Improvements in the Treatment of High-Risk Thyroid Cancer)

  • 이은경
    • 대한두경부종양학회지
    • /
    • 제38권1호
    • /
    • pp.1-9
    • /
    • 2022
  • Thyroid cancer is one of the slow-growing tumors with excellent oncological outcomes. However, a small set of patients with unexpectedly severe outcomes are usually ignored. Anaplastic thyroid cancer (ATC) remains one of the most aggressive and lethal solid tumors. Recently, dabrafenib and trametinib combination therapy or neoadjuvant BRAF induction therapy has shown promising results. In addition, a combination of targeted drugs, immunotherapy, surgery, and radiation therapy can improve overall survival in ATC patients. Another disease for which there is no breakthrough treatment is radioactive iodine-refractory differentiated thyroid cancer (DTC). To date, multikinase inhibitors (sorafenib, lenvatinib) targeting the growth factor signaling pathway have been developed and approved as anticancer agents for patients with advanced DTC. This review includes results from multikinase inhibitors to the emergence of new target molecules, including rearrangements during transformation (RET) and tropomyosin receptor kinase (TRK).

갑상선 결절 1547 예에 대한 임상적고찰 (A Clinical Review of 1547 Cases of Thyroid Nodule - Excluding Diffuse Hyperplasia-)

  • 박원갑;이삼열;오성수;박윤규
    • 대한두경부종양학회지
    • /
    • 제8권2호
    • /
    • pp.82-90
    • /
    • 1992
  • A pathologic review was made of 1547 cases of thyroid nodule during the 20 years from 1970 to 1989 at the department of Head and Neck surgery of Presbyterian Medical Center in Chonju. 1547 cases were analysed in regard to cancer incidence of thyroid nodule, correlation of preoperative diagnosis with pathology and of frozen section diagnosis with final pathology, surgical procedures employed in managing thyroid itself, location of metastatic nodes, further definite procedure in cnacer cases, effectiveness of prophylactic neck dissection with lymph node pathology. The results are summarized as follows: 1) The cancer incidence of thyroid nodule was 21.7%. 2) The incidence of thyroid cnacer in total neoplasms increased from 1.6% to 2.9%. 3) The thyroid cancer was prevalent in female(5.9:1) and in fifth, fourth and sixth decade of life. 4) The incidence of solitary cold nodule in thyroid cancer was 72.7% (210/289). S) The incidence of thyroid cancer in solitary cold nodule was 28.7% (210/782). 6) The false negative of frozen section (1240 cases) was 19.8%. 7) Histologically, well differentiated carcinoma comprises about 94% of all cases and papillary carcinoma was 78.5% of all cases 8) The most frequent lymphatic metastasis was pre- & paratrachel nodes(63.3%), followed by Level III(50%) and Level II(47.7%). 9) 47.7% among 130 cases of papillary adenocarcinoma and 12.5% among 16 cases of follicular adenocarcinoma, each group treated with prophylactic neck dissection, were confirmed to be occult cervical node metastasis.

  • PDF

두경부 편평 세포암에서 예후인자로서의 p53 발현 (The Overexpression of p53 in Head and Neck Squamous Cell Carcinoma as Prognostic Marker)

  • 정승원;이형석;박철원;박용욱;박찬금;장세진;태경
    • 대한두경부종양학회지
    • /
    • 제17권2호
    • /
    • pp.169-173
    • /
    • 2001
  • Objectives: The p53 tumor suppressor gene encodes a nuclear transcription factor that is critical regulator of cell growth and proliferation through its action in cell-cycle checkpoint control. The wide variety of stressful stmuli which include DNA damage, hypoxia, heat shock, metabolic changes activate the p53 protein, which in turn drives a series of events that culminate either in cell cycle arrest or apoptosis. Mutations of the p53 gene is the most common genetic alteration in human cancer. This gene is altered in approximately 40-60% of head and neck cancers. Whereas the wild-type form of the p53 protein plays a central role in cell-cycle control in response to DNA damage, most of the mutant forms are unable to do so. The high levels of p53 protein expression in tissues are related to the increased cellular proliferative activity and may be associated with the poor clinical outcome. To determine whether the expression of the p53 protein has prognostic significance and is associated with patterns of treatment failure in head and neck squamous cell carcinoma (HNSCC), We analyzed p53 overexpression in 40 cases of HNSCC. Materials and Methods: Immunohistochemical analysis with a monoclonal antibody (DO7) specific for p53 protein was used to detect expression of the protein in formalin-fixed, paraffin-embedded tumor samples from 40 HNSCC. We evaluated p53 protein expression and analyzed the relationship between the p53 overexpression and age, sex, primary tumor site, stage, survival rate, recurrence. All reported P values resulted from two-sided statistical tests. Results: Overexpression of p53 was detected in 20 cases(50%) among 40 cases of HNSCC. The p53 overexpression was not associated with age, sex, primary tumor site, stage, recurrence and survival rate. Conclusions: In our results, p53 was not significant prognostic factor in HNSCC. Based on many previous studies, It is evident that p53 has a certain role in tumorigenesis of HNSCC. So, the further study is needed to evaluate the prognostic significance of p53 in HNSCC.

  • PDF

ERCC1 Expression Can Predict Response to Platinum-Based Induction Chemotherapy in Head and Neck Cancer Cases

  • Ameri, Ahmad;Mortazavi, Nafiseh;Ahmadi, Helaleh Khoshbakht;Novin, Kambiz
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제17권sup3호
    • /
    • pp.87-91
    • /
    • 2016
  • To investigate whether excision repair cross complementing-group1 (ERCC1) expression status could serve as a bio-predictor of response to platinum-based induction chemotherapy for head and neck cancers (HNCs) patients with a diagnosis of epithelial HNC were studied retrospectively. Paraffin embedded tumor samples of the patients were analyzed by reverse transcription-polymerase chain reaction (RT-PCR) to determine ERCC1 expression status and its correlation with response to platinum-based induction chemotherapy was investigated. Of 44 included patients, 33 were male (75%) and 11 were female (25%) with a mean age of 53 years. Some 36% of patients whose tumor samples had high ERCC1 expression showed no response to induction chemotherapy. The value for patients with low ERCC1 expression was 9% and the difference was statistically significant (p=0.03). The ERCC1 expression state did not significantly vary between patient groups according to sex, age, primary tumor site, and tumor and node stage. Our study indicates that ERCC1 expression status detected by RT-PCR might serve as a bio-predictor of response to platinum-based induction chemotherapy for epithelial HNCs.

고선량율 강내 조사를 이용한 두경부암의 방사선 치료 (Radiation Therapy of Head and Neck Cancer with CO-60 HDR Transcatheteric Irradiation)

  • 신세원;김성규;김명세
    • Journal of Yeungnam Medical Science
    • /
    • 제7권2호
    • /
    • pp.109-114
    • /
    • 1990
  • 저자들은 두경부암의 포괄적인 치료의 일부로서 외부 방사선 조사와 고선량율 경관조사를 시행하여 12명중 9명에서 완전 관해를 얻었으며, 치료중이나 치료후 경관조사와 직접 관련된 급성 부작용이나 합병중의 발생이 없었다. 그러나 대상환자가 적고 추적기간이 짧은관계로 생존율의 향상은 추측하기 어려우나 완전 관해를 얻은 환자는 장기간 무병 상태로 추적되고 있어서 외부방사선 조사와 경관 조사는 두경부암 치료에 큰 역할을 하리라 기대된다.

  • PDF